Proteo, Inc. Stock

Proteo, Inc. is a clinical stage drug development company that is focused on the development of anti-inflammatory treatments for rare diseases. Its drug candidate Tiprelestat (also known as Elafin) is used for the treatment of acute postoperative inflammatory complications, in particular after esophageal cancer surgery. Elafin is also used for the treatment of pulmonary arterial hypertension, for preventing complications of organ transplantation and for treatment of acute respiratory distress syndrome (ARDS). The Company has obtained Orphan drug designations within the European Union for the use of Elafin for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension as well as for the treatment of esophageal cancer. Within the United States, it has obtained Orphan drug designations for the use of Elafin for the treatment of pulmonary arterial hypertension as well as for the prevention of inflammatory complications of transthoracic esophagectomy.